Loss of the inferior olive-climbing fiber input to the cerebellar cortex after treatment with the neurotoxin 3-acetylpyridine (3-AP) has been reported to double the simple spike activity of the cerebellar Purkinje cell and eliminates complex spike activity. This is quickly followed by a three-to fourfold increase in Purkinje cell mRNA for the 67 kDa form of glutamic acid decarboxylase (GAD), a synthetic enzyme for the neurotransmitter GABA. Treatment with the indirectly acting sympathomimetic amphetamine or the direct acting p2 adrenergic agonist clenbuterol inhibited the increase in GAD,, mRNA, and this inhibition was blocked by pretreatment with the 6 receptor antagonist propranolol.
Loss of the inferior olive-climbing fiber input to the cerebellar cortex after treatment with the neurotoxin 3-acetylpyridine (3-AP) has been reported to double the simple spike activity of the cerebellar Purkinje cell and eliminates complex spike activity. This is quickly followed by a three-to fourfold increase in Purkinje cell mRNA for the 67 kDa form of glutamic acid decarboxylase (GAD), a synthetic enzyme for the neurotransmitter GABA. Treatment with the indirectly acting sympathomimetic amphetamine or the direct acting p2 adrenergic agonist clenbuterol inhibited the increase in GAD,, mRNA, and this inhibition was blocked by pretreatment with the 6 receptor antagonist propranolol.
The activity-enhancing effect of 3-AP treatment on cerebellar neurons was confirmed by extracellular recordings.
Clenbuterol treatment prevented the increase in neuronal firing without altering lesion induction or the loss of complex spikes, and propranolol treatment produced a partial reversal of the inhibitory effect of clenbuterol on the neuronal firing rate. These results suggest that 6 receptor-mediated effects on cerebellar neuronal activity may prevent the increase in mRNA levels, but that firing rate-independent P-mediated effects on genomic expression may also play a role. A role for noradrenergic systems in modulating GAD,, mRNA is also supported by the finding that reducing endogenous cerebellar norepinephrine levels by treatment with reserpine increased Purkinje cell GAD,, mRNA levels (250% of control), and this also was inhibited by clenbuterol treatment.
Key words: glutamic acid decarboxylase; Purkinje cell; climbing fiber lesions; cerebellum; GAD,, mRNA; P-adrenergic receptors; clenbuterol; amphetamine; reserpine; norepinephrine; 3-acetylpyridine The neurotransmitter GABA is an important inhibitory modulator of neural activity throughout the CNS. GABA is synthesized from its substrate, glutamate, in a single step by the pyridoxal phosphate (PLP)-dependent enzyme glutamic acid decarboqlase (GAD). Recent work indicates that two independent genes code for GAD, producing two forms of the enzyme, GAD,, and GAD,, (Erlander et al., 1991; Bu et al., 1992) . The two forms differ in their affinity for PLP: GAD,, is constitutively bound to PLP, whereas GAD,, cycles through active (bound) and inactive (unbound) states (Porter and Martin, 1988; Kaufman et al., 1991; Martin et al., 1991) . The mRNAs coding for both GAD enzymes are coexpressed by GABAergic neurons in most brain areas (Oertel et al., 1981; Kaufman et al., 1991) , but in differing proportions in specific neuronal types (Esclapez et al., 1993 (Esclapez et al., , 1994 .
The cerebellar Purkinje cell is a large GABAergic neuron that can express high levels of GAD,, mRNA (Erlander et al., 1991; Esclapez et al., 1994) . This cell receives a well described system of excitatory and inhibitory inputs, and it is possible to modify or mimic these inputs pharmacologically to alter Purkinje cell firing rates. Lesion of the inferior olive-climbing fiber input to the Purkinje cell by treatment with the neurotoxin 3-acetylpyridine (3-AP) eliminates low-frequency Purkinje cell complex spike activity, and produces large increases in the simple spike-firing rate of the neuron within 3-5 hr after treatment (Desclin, 1974; Benedetti et al., 1984; Lopiano and Savio, 1986) . Alternatively, Purkinje cell firing rates can be reduced by activation of intrinsic inhibitory neurons (e.g., stellate and basket cells) or systems such as the noradrenergic input arising from the locus coeruleus (Siggins et al., 1971; Freedman et al., 1977; Schultz et al., 1981; Moises et al., 1983 Moises et al., , 1990 BickfordWimer et al., 1991; Tan and Collewijn, 1992) . The noradrenergic effects appear to be mediated, in part, by activation of Purkinje cell p receptors and can be mimicked by treatment with adrenergic agonists (Siggins et al., 1971; Schultz et al., 1981; Moises et al., 1983 Moises et al., , 1990 McEligott et al., 1986; Bickford-Wimer et al., 1991; Llano and Gerschenfeld, 1993) .
The increase in Purkinje cell firing produced by 3-AP lesions of the climbing fiber input is followed by significant increases in GAD activity in the Purkinje cell terminals (Oltmans et al., 1985 (Oltmans et al., , 1986 Sukin et al., 1987; Litwak et al., 1990) . Although the origin of the increase in GAD activity has not been established definitively, increased GAD,, mRNA levels in Purkinje cell soma at 7 d after lesion have been reported (Litwak et al., 1991) , suggesting the possibility that increased translation from the abundant message could account for the increased GAD activity. This hypothesis is supported by a recent report that Purkinje cell GAD,, mRNA levels are significantly increased 8 hr after 3-AP treatment (Drengler and Oltmans, 1993) . This represents a time when cell firing rates have been increased for 3-4 hr (Desclin and Escubi, 1974) but before the time that increases in GAD activity can be measured (24-48 hr) (Sukin et al., 1987; Litwak et al., 1991) . It appears that sustained increases in Purkinje cell firing produce a rapid induction of GAD message, which may induce the later increase in GAD activity.
The relatively brief (8 hr) period required to reliably produce increases in Purkinje cell GAD,, mRNA levels was used in the current work to study the effects of specific pharmacological treatments on the increase in GAD,, message, and to evaluate the possibility that the increased GAD,, mRNA levels were the result of increased firing rates. As noted above, the noradrenergic input to the Purkinje cell inhibits Purkinje cell firing. Therefore, treatment with centrally acting adrenergic agents such as the & agonist clenbuterol (Tondo et al., 1985) or the indirectly acting sympathomimetic amphetamine was combined with 3-AP toxin treatment, and the effects on GAD,, mRNA levels were determined. In addition, in experiments with separate groups of animals the effects of selected treatments on cerebellar neuronal firing rates were assessed using extracellular recordings.
MATERIALS AND METHODS
Male Sprague-Dawley rats Zelienople, PA) were administered the neurotoxin 3-AP (75 m&kg, i.p.) prepared in isotonic saline to lesion the climbing fiber system. Nonlesion controls were administered isotonic saline. In studies involving climbing fiber lesions, animals were killed by decapitation 8 hr after 3-AP treatment. This time interval allows toxin-induced destruction of the olivary cell with the subsequent sustained increases in Purkinje cell firing rates for a period of -4 hr (Desclin and Colin, 1980) , and a significant increase in Purkinje cell GAD,, mRNA levels (Drengler and Oltmans, 1993) . Animals were administered different adrenergic agonists and antagonists in conjunction with the 3-AP treatment.
To directly stimulate Purkinje cell p receptors, the p2 adrenergic agonist clenbuterol (10 mg/kg), which crosses the blood-brain barrier and interacts with Purkinje cell pa receptors (Tondo et al., 1985; Conway et al., 1987; Vos et al., 1987) was administered 40 min before treatment with 3-AP. To stimulate endogenous norepinephrine release and increase synaptic norepinephrine levels in the cerebellum, the indirectly acting sympathomimetic d-amphetamine sulfate (2 mg/kg) was administered 20 min before treatment with 3-AP (Carlsson et al., 1966; Azzaro and Rutledge, 1973) . To test for p receptor specificity of effects, the nonselective p antagonist propranolol (9.5 mg/kg) was administered 20 min before treatment with either clenbuterol or amphetamine, and then again 4 hr later. Ail drugs were dissolved in isotonic saline. The drug doses used and the frequency of administration were selected based on preliminary experiments using values from the literature indicating both an effective CNS level and a duration of action sufficient to cover the period of study (Dring et al., 1970; Tondo et al., 1985; Ordway et al., 1987; Vos et al., 1987) . To assess the effect of activating noradrenergic systems on cerebellar GAD,, mRNA levels in nonlesioned animals, amphetamine sulfate (2 mg/kg) was administered to normal animals every 12 hr, and the animals were killed 40 hr after the initial injection.
To attenuate central noradrenergic effects, reserpine (2 mgjkg in vehicle) was administered twice (0 and 24 hr) to deplete-endogenous norepinephrine (Alpers and Shore, 1969 : Giachetti and Shore. 1978 : Oltmans et al.. 1980 . and animals were killed 40 hr after the initial injection.
The interaction of reserpine with other treatments on GAD,, mRNA levels was also assessed. Reserpine (2 mg/kg) was administered, followed 16 hr later by either clenbuterol (10 mg/kg) or 3-AP (75 mg/kg). schell et al., 1986) .
Prehybridization and posthybridization treatments were performed as described by Litwak et al. (1990) . Hybridization was performed by adding 3-6 ng of probe (4 X 10' dpm/mg) to each cerebellar section. The slides were hybridized in humid chambers at 50°C for 3.5 hr. After posthybridization washes, the sections were dipped in NTB2 emulsion to detect the presence of hybridized radioisotope-labeled probe. (Desclin, 1974; Desclin and Escubi, 1974; Desclin and Cohn, 1980) and early onset motor symptoms (hypotonia, ataxia, and limb splaying), which reliably reflect extensive olivary damage.
In the current studies, histological confirmation of the lesion was precluded by the incompatibility of the brief period (8 hr) under evaluation with the period required to observe cell loss with standard histological techniques (Desclin, 1974; Desclin and Escubi, 1974) . Therefore, to indirectly confirm lesion presence, animals were observed for the presence of motor signs noted above.
To obtain a more complete histological profile, in two separate groups of animals (5 animals/group), 3-AP or a clenbuterol + 3-AP combination was administered.
After a 3 d survival period, the animals were killed by an overdose of sodium pentobarbital, perfused transcardially with saline, and neutral-buffered formalin, and the brainstem containing the inferior olive was placed in 20% sucrose for at least 24 hr. The brainstems were sectioned at 30 km in a freezing microtome and stained with cresyl violet, and alternate sections were examined at 250X magnification for the presence of spared cells in the inferior olive. The locations of surviving cells were assessed using the studies of Apps (1990) and Azizi and Woodward (1987) as guides. One animal treated with 3-AP alone died before the 3 d period was complete.
Electrophysiology. Nine rats were treated with isotonic saline followed 40 min later by 3-AP (75 mg/kg) (3-AP group). Six rats received 10 mg/kg clenbuterol followed 40 min later by 3-AP (3-AP + clenbuterol). Six rats received 9.5 mg/kg propranolol followed 20 min later by 10 mg/kg clenbuterol and 40 min later by 3-AP, and two additional rats were also administered a second propranolol injection 4 hr after the first treatment.
These two treatments did not produce different effects, and the results were consolidated into a single group (3-AP + clenbuterol + propranolol). Control rats received saline treatment only (saline). Two hours after 3-AP injection, all rats were anesthetized with 1.9 gm/kg urethane and prepared surgically for extracellular recordings from lobules V and VI of the cerebellar cortex as described previously (Stratton et al., 1988 Most of the large cells encountered in the high-activity regions in normal animals are Purkinje cells, and it is likely that this is still the case after toxin treatment.
Therefore, electrophysiological recordings were used to sample simple spike activity in putative Purkinje cells in toxin-treated rats. Only a few cells in these animals retained complex spike activity at the 3-5.5 hr post-treatment interval.
As in other studies using 3-AP-treated rats (Montarolo et al., 1982; 
RESULTS

Lesion confirmation
In all experiments, motor symptoms (e.g., ataxia and hypotonia) consistent with the presence of an effective olivary-climbing fiber lesion were reliably observed within 4-6 hr after treatment in 3-AP-treated animals (regardless of the presence of clenbuterol). In the group of animals evaluated after a 3 d post-treatment period, extensive loss of cells in the inferior olive was found (see below).
Lesion and drug effects on Purkinje cell GAD,, mRNA In agreement with previous findings (Drengler and Oltmans, 1993) , at 8 hr after treatment 3-AP produced a large increase in Purkinje cell GAD,, mRNA levels (342% of saline-treated control value; Table 1 ). When 3-AP treatment was preceded (40 min) by administration of the & adrenergic agonist clenbuterol, there was no increase in GAD,, mRNA levels (98% of control). Pretreatment of the 3-AP + clenbuterol combination with the p adrenergic receptor blocker propranolol produced GAD,, mRNA levels (379% of control) comparable with those seen with 3-AP treatment alone. Taken together, these data suggest that GAD,, mRNA levels can be regulated through /3 receptors. In Figure 1 representative dark-field photomicrographs of cerebellar emulsions labeled with the GAD,, mRNA antisense probe are shown. Heavy labeling of Purkinje cells in 3-AP-treated animals (B) can be compared with the relatively light labeling in controls (A). Clenbuterol treatment prevented the 3-AP effect, substantially reducing grain density in the lesioned animals, although a few cells did show high grain densities (C), whereas propranolol reversed the clenbuterol effect, reinstating the heavy labeling densities found with 3-AP alone (0).
These results indicate that & receptor activation prevents the 3-AP lesion-induced increase in Purkinje cell GAD,, mRNA levels, and that the inhibition can be reversed by p receptor blockade. In the cerebellum, the primary catecholamine neurotransmitter is norepinephrine, which at physiological concentrations stimulates primarily /3i receptors, with decreased potency for & receptors (Goodman and Gilman, 1985) . To assess the ability of the endogenous neurotransmitter to prevent the 3-AP effect, amphetamine, an indirectly acting sympathomimetic, was administered to increase synaptic norepinephrine levels in 3-AP-treated animals.
The 3-AP treatment again produced a large increase in Purkinje cell GAD,, mRNA levels (479% of control), which was prevented by amphetamine treatment (132% of control; Table 2 ). When the p receptor blocker propranolol was added to the 3-AP + amphetamine combination, Purkinje cell GAD,, mRNA levels were again increased (373% of control; not significantly different from 3-AP treatment alone). The effects of amphetamine on 3-AP stimulation of GAD,, mRNA levels parallel those of the previous 3-AP + clenbuterol experiments.
To assess the possibility that adrenergic input to the cerebellum might help regulate Purkinje cell GAD,, mRNA levels, separate groups of animals (n = g/group) were administered amphetamine or reserpine (to increase or reduce endogenous noradrenergic activity, respectively) over a 40 hr period. Treatment with amphetamine did not appear to alter basal GAD,, mRNA levels (108 ? 32% of control, p > 0.05). In contrast, reserpine treatment produced a significant increase in GAD,, mRNA levels (347 ? 50% of control, p < 0.01) (control grain density = 0.0215 ? 0.006) similar in magnitude to that seen after 3-AP treatment.
The reserpine effects were studied further by administration of a single reserpine injection followed 16 hr later by either clenbuterol or 3-AP, and animals were killed 8 hr after the second treatment (24 hr after initial reserpine treatment). With the shorter 24 hr treatment period, reserpine produced a slightly smaller but still significant increase in GAD,, mRNA levels Table 2 . Purkinje cell GAD,, mRNA levels (mean 2 SD) after 3-AP (8 br): effects of amphetamine and amphetamine + propranolol treatment Treatment GAD mRNA density (% of saline control) (n) Saline (0.00630)** 100 k 20 (8) 3-AP 479 ir 102* (6) 3-AP + amphetamine 132 t 45 (7) 3-AP + amphetamine + propranolol 373 -c 99* (7) * Differs significantly from sal i ne and 3.AP + amphetamine treatments @ < 0.01). ** GAD,, mRNA grain density values i n sal i ne controls (see Table 1 ). Figure 1 . Dark-field photomicrographs of in situ labeling using the GAD,, mRNA antisense probe in cerebellar Purkinje cells. Heavy labeling in a row of Purkinje cells from 3-AP-treated animals (B) can be compared with labeling in control animals (A) (u~ows point to individual Purkinje cells). Clenbuterol treatment (C) substantially reduced labeling in 3-AP-treated animals, and most cells appeared similar to those in control animals, although some cells did appear to show some increase (top right arrow in C). Combining propranolol treatment with clenbuterol in 3-AP-treated animals (0) reinstated the heavy labeling seen with 3-AP alone.
(250% of control; Table 3 ). Clenbuterol treatment prevented the reserpine effect (152% of control,p > 0.05). Combining reserpine treatment with 3-AP did not further increase the change seen with 3-AP alone (382 vs 348% of control). Like amphetamine, clenbuterol treatment alone (112% of control) had no effect on the GAD,, mRNA levels. Taken together, the results of these experiments (Tables l-3 ) suggest a /3 receptor-mediated noradrenergic contribution to the regulation of GAD,, mRNA levels in the cerebellar Purkinje cell.
Clenbuterol effects on inferior olive lesions It is possible that clenbuterol prevented increases in Purkinje cell GAD,, mRNA not by a p receptor-mediated effect, but by preventing 3-AP lesion induction. To determine the effectiveness of Table 1 ).
3-AP in producing inferior olive-climbing fiber lesions in the presence of clenbuterol, a group of animals was treated with 3-AP or 3-AP + clenbuterol, and extent of lesion was assessed 3 d after lesion. All of these animals showed clear behavioral evidence of 3-AP treatment. The two animals rated as most severely affected received 3-AP alone. The clenbuterol-pretreated animals could not be reliably distinguished from the remaining rats treated only with 3-AP.
Tissue analysis revealed widespread cell loss throughout the inferior olive in all cases, but surviving neurons could also be found. Surviving cells were found most frequently in subnucleus c of the medial accessory olive (MAO) and in the most ventral and lateral region of the principal olive (PO). In clenbuterolpretreated subjects, two animals had relatively high densities of surviving cells in MAO subnucleus c. This was defined as three or more sections in which 10 or more surviving cells could be seen. Two animals had moderate densities (i.e., S-10 cells/section in 3 or more sections) in this area. The remaining animal had relatively light sparing with <5 cells evident/section. Applying these criteria in animals treated only with 3-AP, one animal was found to have a high density of spared cells in subnucleus c. One other animal showed a moderate density of sparing, and the remaining two animals showed a light density. In other regions of the inferior olive, including the PO, sparing was similar in both groups when present.
According to the work of Desclin and Escubi (1974) it may take up to 2 weeks for the full toxic effect of 3-AP in the inferior olive to be observed histologically as somal destruction. A much more rapid method of evaluating functional loss of inferior olive is by observing ataxic movements. In the cases reported here, 3-AP produced characteristic motor dysfunction (and, thus, olivary damage) regardless of drug pretreatment.
This finding is supported further by the electrophysiology studies of Purkinje cells reported below.
3-AP and drug effects on Purkinje cell electrophysiology To identify possible mechanisms by which treatment with adrenergic agonists might block the lesion-induced increase in GAD,, mRNA, cerebellar neuronal activity was studied using extracellular recording techniques. Qualitatively, in all animals receiving 3-AP treatment (3-AP, 3-AP + clenbuterol, and 3-AP + clenbuterol + propranolol groups), only 18 of 74 cells were identified unequivocally as Purkinje cells, because they retained complex spike activity. Of these 18 cells, 13 were recorded early in the post-treatment period (~4 hr after treatment) before the time the full lesion effect of 3-AP may have been expressed. In the 18 cells with complex spike activity, the firing rates were similar to those found in control animals treated with saline only (19.8 vs 21.1 Hz, respectively), and did not differ significantly between the treated groups ( Table 4 ). The difficulty experienced in locating cells with complex spikes in the presumed Purkinje cell layer indicates that the 3-AP treatment was effective in removing the climbing fiber input to the Purkinje cells.
In animals treated with 3-AP alone, the firing rates of cells in the high-activity layer not showing complex spike activity (n = 13) were significantly higher than both those of cells retaining complex activity and those from saline-treated controls (255% of control rate, p < 0.001 for both comparisons; Table 4 ). This confirms the effectiveness of the 3-AP treatment in increasing cerebellar neuronal activity in the high-activity layers containing Purkinje cells. Treatment of 3-AP animals with clenbuterol significantly modified this effect. In the 3-AP + clenbuterol group, firing rates were reduced compared with 3-AP only (t = 4.02,~ < 0.001) and were not significantly higher than in saline controls (118% of control rate, t = 0.71,~ > 0.05). Addition of propranolol to the 3-AP + clenbuterol regimen partially reversed the clenbuterol effect, producing firing rates significantly higher than in either saline controls (163% of control rate; t = 3.89, p < 0.001) or the 3-AP + clenbuterol group (t = 2.20,~ < 0.05), but less than those in the 3-AP alone group (t = 4.26,~ < 0.001). Thus, changes in electrophysiological responses of cells to drug treatments precede and predict changes in GAD,, mRNA levels observed later.
DISCUSSION
The in situ hybridization results confirmed our earlier observations that lesions of the olivo-cerebellar climbing fiber system produced rapid increases in Purkinje cell GAD,, mRNA (Drengler and Oltmans, 1993) . The increases in GAD,, message were accompanied by increased cerebellar neuronal firing rates in the high-activity layer, which contains predominantly Purkinje cells, suggesting a causal relationship between these events. The finding of increased GAD,, mRNA specifically in the Purkinje cells also supports the idea that the Purkinje cells were the source of the increased electrical activity. Treatment of lesioned animals with the centrally acting p2 agonist clenbuterol prevented both the increase in GAD,, mRNA levels and the increase in cell firing rates, strengthening the correlation between firing rates and et al. . P-Agonists Inhibit Increases i n Cerebel l ar GAD,, mRNA GAD,, mRNA increases. Blocking p receptors with the antagonist propranolol, although completely preventing the clenbuterol inhibitory effect on GAD,, mRNA levels, only partially prevented its inhibitory effect on firing rates. This suggests that the effects of clenbuterol on firing rates may not be the only p receptormediated factor in the regulation of GAD,, message, and may indicate that the activation of intracellular pathways with inhibitory effects on GAD,, gene transcription is also involved (Segovia et al., 1991) . Alternatively, it is possible that other complicating factors (e.g., a propranolol-general anesthetic interaction) in the electrophysiological experiments produced an inhibitory effect on firing rates not present in nonanesthetized animals used for the in situ hybridization studies. In addition to the direct p2 adrenergic agonist, treatment with the indirectly acting sympathomimetic amphetamine prevented the lesion-induced increase in GAD,, mRNA levels. As with clenbuterol, this effect was reversed by propranolol, indicating that the endogenous cerebellar norepinephrine was able to modulate the lesion effect on the GAD,, mRNA, and suggesting that the noradrenergic input to the cerebellum may serve a regulatory role in cerebellar GAD,, mRNA production. Such a role is supported by the observations of Segovia et al. (1991) , who reported that in GAD,, gene transfection studies in C6 neuroglioma cells, CAMP analogs decrease GAD,, mRNA levels. The mechanisms mediating these effects are not clear, because no CAMP-responsive elements have yet been discovered in the GAD,, gene.
The mechanisms underlying the effects on cerebellar GAD,, mRNA of these two adrenergic agents, the direct-acting clenbuterol and the indirect-acting amphetamine, are not clear. In the cerebellum, the dominant adrenergic receptor subtype is p2 (90-98% of total /3 receptors) (Dolphin et al., 1979; Sutin and Minneman, 1985) , which would provide a target for clenbuterol but would be much less favorable for the predominantly pi-selective norepinephrine released by amphetamine treatment. This may indicate that the released norepinephrine can efficiently activate the less abundant pi receptors to inhibit GAD,, mRNA production or, regardless of its low affinity, that norepinephrine recruits sufficient B2 receptors to induce this effect. Both pi and & receptors couple to G, to stimulate adenylyl cyclase (Sessler et al., 1989) thereby providing a common pathway for both clenbuterol and amphetamine/norepinephrine to prevent the 3-AP induction of GAD,, mRNA.
The finding that clenbuterol treatment inhibited the increase in GAD,, mRNA suggests that under the appropriate conditions, clenbuterol might have a therapeutic efficacy in modifying cerebellar activity, yet produce minimal effects at other sites in the CNS where the predominate /3 receptor type is pi (Dolphin et al., 1979) . It is also interesting to note that regulation of GAD,, mRNA levels under nonstimulated conditions may not be the same as under conditions of increased neural activity, because neither clenbuterol nor amphetamine appeared to affect baseline GAD,, mRNA levels. This may mean that the noradrenergic system can modulate increased production of message, but that it does not influence constitutive expression.
The large postlesion increase in Purkinje cell GAD,, mRNA produced intense labeling of the Purkinje cell layer in 3-APtreated animals. Substantial labeling also appeared to be present in the molecular and granular cell layers of these animals, but was not a prominent feature in controls. Although grain density was not quantitated in these other areas, interneurons of both the molecular and the granular layers are GABAergic and might be expected to have GAD mRNA present. The appearance of the increased labeling was not consistent, however, with the interpretation that it was derived from the interneurons of these layers. Rather, the labeling was most intense close to the Purkinje cell body and decreased in intensity with increasing distance from the soma. This suggests that the labeling may represent mRNA extending into the dendrites and proximal axons of the Purkinje cell itself. Such a possibility has been suggested by others (Davis et al., 1990; Kleiman et al., 1993; Esclapez et al., 1994) .
Although loss of the Purkinje cell complex spike activity is believed to be primarily responsible for the increase in simple spike firing after olivary lesions, a lesion effect on noradrenergic release produced by the climbing fiber denervation might also contribute. There is evidence of presynaptic NMDA receptors in the cerebellum, which facilitate noradrenergic release (Wood, 1991) . Climbing fiber activation could stimulate these receptors by release of glutamate or aspartate. Loss of the climbing fiber input would potentially reduce stimulation of these receptors, thereby decreasing norepinephrine release and removing its inhibitory effects on the Purkinje cell. The subsequent increase in Purkinje cell activity would be expected to increase GAD,, mRNA levels. This hypothesis is consistent with the current findings that cerebellar norepinephrine depletion by reserpine treatment significantly increased Purkinje cell GAD,, mRNA levels. A common mechanism may be suggested by which either destruction of climbing fiber input or reserpine depletion could decrease synaptic norepinephrine availability, preventing its inhibition of cell firing and thereby producing increased GAD,, mRNA levels.
Behavioral effects of 3-AP treatment were noticeable by 4-6 hr after toxin treatment. Control animals could easily be distinguished from those receiving toxin by comparing movement characteristics (ataxia, limb splaying, and head swinging) of the two groups. Qualitative comparison of motor dysfunction between 3-AP-and 3-AP + clenbuterol-treated animals does not present as clear a picture. The few animals presenting the most severe movement abnormalities were always treated with 3-AP alone, and the animals demonstrating delayed and milder dysfunction were always 3-AP + clenbuterol-treated, but there was much overlap in the two treatment groups. Thus, in these acutely treated animals, for the brief period of time the animals were available for observation, it was not possible to classify 3-AP-or 3-AP + clenbuterol-treated animals unequivocally by observing their movements, even though both groups could be easily distinguished from controls. For the toxin-and drug-treated animals maintained for a longer survival period (3 d) for histological analysis, again, there were no definitive differences between 3-AP and 3-AP + clenbuterol groups in the severity of motor behaviors. This is not unexpected, however, because the time of clenbuterol presence in these animals would be limited, after which the lesion effect would be dominant. The effect on motor parameters of more sustained clenbuterol treatment in 3-AP-treated animals was not assessed in the current study.
In agreement with the behavioral observations, histological evaluation of the inferior olive in animals cotreated with 3-AP and clenbuterol revealed that the lesion magnitudes were not discriminably different from those obtained in tissue treated with 3-AP alone. This finding is also supported by the results of the electrophysiological analysis-of the 20 cells recorded from the 3-AP + clenbuterol group, 17 did not demonstrate complex spike activity. Because complex spikes are generated by the olivary climbing fiber input to the Purkinje cell, the histological and electrophysiological data indicate that 3-AP retained its cytotoxic et al. l P-Agonists Inhibit Increases i n Cerebel l ar GAD,, mRNA effect in the inferior olive even in the presence of clenbuterol. Thus, changes in GAD,, message after 3-AP + clenbuterol treatment were apparently attributable to /3 receptor-mediated events and not to inhibition of the lesion-inducing effect of 3-AP. In summary, the results of the current work indicate a rapid increase in cerebellar Purkinje cell GAD,, mRNA associated with the loss of the climbing fiber input to the cerebellar cortex and the subsequent increase in presumed Purkinje cell firing rates. p receptor-mediated events can prevent this effect, but it is unclear whether this is a result of a direct modulation of cell firing rate or of unknown secondary mechanisms. Although exact mechanisms are not clear, there appears to be a role for the adrenergic input to the cerebellum in modulating the Purkinje cell GABAergic system.
